A. Civelek
University of Louisville
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Civelek.
American Journal of Clinical Oncology | 2015
Aashish D. Bhatt; Moataz N. El-Ghamry; N.E. Dunlap; Geetika Bhatt; Matthew M. Harkenrider; John C. Schuler; Albert Zacarias; A. Civelek; Jianmin Pan; Shesh N. Rai; Shiao Y. Woo
Objectives:To quantify gross tumor volume (GTV) change during stereotactic body radiotherapy (SBRT) and on first follow-up, as well as to evaluate for any predictive prognostic risk factors related to GTV decrease. An attempt was also made to identify the potential timing for adaptive SBRT. Methods:Twenty-five tumors in 24 consecutive patients were treated with SBRT to total dose of 50 Gy in 5 fractions. Median age was 72.5 years. Tumor stage was T1, 68%; T2, 20%; and other, 12%. The GTVs of on the 5 cone-beam computed tomographies (CBCT1-5) obtained before each fraction and the first follow-up CT (CTPOST) were analyzed. Results:Median time from diagnosis to initiation of radiotherapy was 64 days. GTV on CBCT1 was the baseline for comparison. GTV decreased by a mean of 7% on CBCT2 (P=0.148), 11% on CBCT3 (P=0.364), 19% on CBCT4 (P=0.0021), and 32% on CBCT5 (P=0.0004). Univariate analyses of GTV shrinkage was significantly associated with “time from CBCT5 to CTPOST” (P=0.027) and “T-stage” (P=0.002). In multivariate analyses, “T-stage” remained significant with T1 tumors showing greater GTV shrinkage than T2 tumors. Conclusions:Significant decrease in GTV volume based on daily CBCT was demonstrated during SBRT treatment. Adaptive SBRT has the potential to minimize integral dose to the surrounding normal tissues without compromising GTV coverage.
Clinical Nuclear Medicine | 2013
Jonathan Joshi; George M. Kushner; Geetika Bhatt; Aashish D. Bhatt; A. Civelek
The incidence of osteonecrosis of the jaw (ONJ) among patients with cancer and metastatic bone disease being treated with bisphosphonates is as high as 10%, which dictates that an understanding of the risk factors, preventative measures, means of early diagnosis, and treatment is critical. Despite ONJ occurring in the clinical setting of intravenous bisphosphonates, there are other causes associated with higher risk of ONJ, such as multiple dental extractions. Overall, it is important for imaging health care professionals to recognize, describe, and understand ONJ to help minimize biopsies and allow proper treatment to begin as soon as possible.
The Journal of Nuclear Medicine | 2012
Xiao-Feng Li; Huijie Jiang; Tao Huang; Junling Li; Huaiyu Zheng; Chin Ng; A. Civelek
Journal of Clinical Oncology | 2017
Geetika Bhatt; Xiao-Feng Li; Angita Jain; Matthew Stephens; A. Civelek
Journal of Clinical Oncology | 2017
Aashish D. Bhatt; Xiao-Feng Li; Geetika Bhatt; Goetz H. Kloecker; Vivek R. Sharma; A. Civelek
Journal of Clinical Oncology | 2017
Geetika Bhatt; Xiao-Feng Li; Vivek R. Sharma; Aashish D. Bhatt; Alex Cambon; Shesh N. Rai; A. Civelek
The Journal of Nuclear Medicine | 2013
Geetika Bhatt; Xiao-Feng Li; A. Civelek
The Journal of Nuclear Medicine | 2013
Geetika Bhatt; Xiao-Feng Li; A. Civelek
The Journal of Nuclear Medicine | 2012
Jonathan Joshi; George M. Kushner; Geetika Bhatt; Aashish D. Bhatt; A. Civelek
The Journal of Nuclear Medicine | 2012
Xiao-Feng Li; A. Civelek